Meningococcemia cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 3: | Line 3: | ||
{{CMG}} ; {{AE}} {{Ammu}} | {{CMG}} ; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
Cost effective analysis study has indicated that a 2-dose series at ages 11 years and 16 years has a similar cost-effectiveness compared with moving the single dose to age 15 years or maintaining the single dose at 11 years. | |||
==Cost-effective Analysis== | ==Cost-effective Analysis== | ||
*As part of the evaluation of the adolescent vaccination program, a cost-effectiveness analysis was performed to compare the cost-effectiveness of the following three vaccination strategies: <ref name=CDC>{{cite web | title = The Centers for Disease Control and Prevention(CDC)| url =http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm}}</ref> | *As part of the evaluation of the adolescent vaccination program, a cost-effectiveness analysis was performed to compare the cost-effectiveness of the following three vaccination strategies: <ref name=CDC>{{cite web | title = The Centers for Disease Control and Prevention(CDC)| url =http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm}}</ref> | ||
Revision as of 13:50, 21 November 2014
|
Meningococcemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Meningococcemia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Meningococcemia cost-effectiveness of therapy |
|
Risk calculators and risk factors for Meningococcemia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Cost effective analysis study has indicated that a 2-dose series at ages 11 years and 16 years has a similar cost-effectiveness compared with moving the single dose to age 15 years or maintaining the single dose at 11 years.
Cost-effective Analysis
- As part of the evaluation of the adolescent vaccination program, a cost-effectiveness analysis was performed to compare the cost-effectiveness of the following three vaccination strategies: [1]
References
- ↑ 1.0 1.1 "The Centers for Disease Control and Prevention(CDC)".
- ↑ Trotter CL, Edmunds WJ (2002). "Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales". BMJ. 324 (7341): 809. PMC 100788. PMID 11934772.
- ↑ Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team (2005). "Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States". Pediatrics. 115 (5): 1220–32. doi:10.1542/peds.2004-2514. PMID 15867028.